About the researcher:
Dr. Richard Furie is a rheumatologist whose activities have focused on patient care, physician education, and clinical research in the area of anti-rheumatic drug development. He directs The Program in Novel Therapeutics, a clinical research program in musculoskeletal disease. He also directs the SLE and Autoimmune Disease Treatment Center, which has become internationally recognized for its role in the development of new therapies for SLE.
Regarded as a senior rheumatologists in the New York metropolitan area, he has been on the Boards of Directors of the local chapters of the Arthritis Foundation and the Lupus Alliance of America and has been a member of the Medical-Scientific Advisory Council of the Lupus Foundation of America as well as its Lupus News editorial board. He also is on the Medical and Scientific Alliance for Lupus Research Scientific Advisory Board as well as the Advisory Board of the SLE Foundation.
Dr. Furie has served on many committees of the American College of Rheumatology, including the College’s Board of Directors. Although often featured as a speaker at national and international conferences, Dr. Furie’s favorite educational venue is at home with the Hofstra Northwell medical students and Northwell Health internal medicine residents.
The goal of Dr. Furie’s proposed research is to investigate the signaling pathways in myeloproliferative diseases over the course of the disease. Understanding these mechanisms may allow for the development of more efficacious and better targeted therapies.
This approach requires samples from individual patients with myeloproliferative diseases. With over 25 years’ experience focusing on the treatment of hematologic malignancies, Dr. Furie has the expertise, leadership and motivation necessary to successfully carry out the proposed work. He has served as principal investigator or co-investigator for many clinical trials involving the treatment of patients with myelodysplastic syndrome and leukemia, including studies involving close collaboration between the clinician and basic science laboratory.
This has been done with great success in chronic lymphocytic leukemia where serial samples over time have been obtained and studied in collaboration with basic science laboratories. Dr. Furie has been an active member of the National Cancer Institute-sponsored Community Clinical Oncology Program, participating in multiple cooperative group clinical trials for patients with hematologic malignancies. He also successfully administered the projects (e.g., staffing, research protections, budget), collaborated with other researchers and produced more than 100 peer-reviewed publications based upon these projects.
As a result of his previous experience, Dr. Furie is aware of the requirements to successfully undertake a clinical trial following good clinical practice guidelines. He has demonstrated a record of successful and productive myeloproliferative disease research in this patient population.
Cornell University College of Arts and Sciences
Cornell University Medical College
The New York Hospital
Field of study: Internal Medicine
The New York Hospital
Field of study: Assistant Resident
Honors and awards
Top Doctors: NY Metro Area
New York Magazine Best Doctors
America’s Top Physicians
- Jacobi AM, Huang W, Wang T, Freimuth W, Sanz I, Furie R, Mackay M, Aranow C, Diamond B, Davidson A. “Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: Extension of a phase II, double-blind, placebo-controlled, dose-ranging study.” Arthritis Rheum 2010; 62(1): 201-210.
- Arad A, Proulle V, Furie RA, Furie BC, Furie B. “β2 glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model.” Blood 2011; 117(12): 3453-9.
- Merrill JT, Buyon JP, Furie RA, Latinis KM, Gordon C, Hsieh HJ, Brunetta P. “Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER).” Lupus. 2011; 20(7):709-16.
- Furie RA, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham W, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF. “A phase 3, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits BLyS, in patients with active systemic lupus erythematosus.” Arthritis Rheum 2011; 63(12):3918-3930.
- Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, Maciuca R, Zhang D, Garg JP, Brunetta P, Appel G; for the LUNAR Investigator Group. “Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab (LUNAR) study.” Arthritis Rheum 2012; 64(4):1215-26.
- Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, Ginzler EM, D’Cruz DP, Doria A, Cooper S, Zhong ZJ, Hough D, Freimuth W, Petri MA. “Effects of belimumab, a B-lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase 3 trials.” Ann Rheum Dis 2012; [Epub ahead of print]
- Horowitz D, Furie R. “Does belimumab reduce disease activity in adults with systemic lupus erythematosus?” Clin Med Rev Ther 2012; 4:71-78.
- Horowitz D, Marder G, Furie R: “Musculoskeletal System: Articular Disease, Bone Metabolism in Systemic Lupus Erythematosus.” Edited by Lahita RG. New York, Elsevier, 2010.
- Bogachuk E, Furie R: “Systemic lupus erythematosus in Perioperative Management of the Patient with Rheumatic Disease.” Edited by Brian Mandell. Springer, in press.